Lenomorelin

The global gastroparesis drugs market is projected to grow by USD 1.42 billion from 2024 to 2028, with a CAGR of 3.69%. Key segments include drug class, disease type, and geography. Prokinetic drugs like metoclopramide and domperidone are significant for managing symptoms. New drugs under development aim to improve treatment outcomes.

Global gastroparesis drugs market to grow by USD 1.42 billion from 2024-2028, driven by rising diabetes prevalence and emerging market opportunities, despite stringent regulatory challenges. Key players include Abbott Laboratories, AbbVie Inc., and others.

UVA study finds high intensity exercise suppresses ghrelin, a hunger hormone, suggesting it's key for appetite suppression in weight loss programs.

High-intensity workouts suppress ghrelin more than moderate exercises, with women showing greater reduction in ghrelin levels post-exercise, suggesting high-intensity exercise may aid appetite suppression and weight loss.

Karolinska Development announces AnaCardio's completion of AC01-FE study and phase 1b of GOAL-HF1, evaluating AC01 in heart failure patients. AC01, a ghrelin-mimicking drug, was safe and well-tolerated in both studies.